Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent (The VAL-SUPPRESS Trial).

Trial Profile

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent (The VAL-SUPPRESS Trial).

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2012

At a glance

  • Drugs Valsartan (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms VAL-SUPPRESS
  • Most Recent Events

    • 05 Apr 2011 Primary endpoint 'Late-loss' has not been met.
    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
    • 17 Aug 2010 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top